Atera can restart growth, if it ships well
- Q1 2026 total revenue was $150.8 million, down 3%, while products and services revenue grew 9%.
- Consumables are the core story: single cell consumables grew 6% and spatial consumables grew 31%.
- Instrument revenue fell 24% as customers waited for Atera, the new spatial platform due to ship in H2 2026.
- The bull case is a classic razor and blade setup, with tools placed first and high-margin consumables sold later.
- The bear case is timing: if Atera is late or weak, the instrument pause could last longer than planned.
- Finn’s score is mixed because growth is improving, but the stock still carries a hard valuation question.
Atera is now the swing factor
10x Genomics entered 2026 with a cleaner story than it had in 2025. The company’s recurring consumables business is growing again, and Q1 showed demand in both single cell and spatial biology. That matters because consumables are the part of the model investors most want to own.
The new twist is Atera. Management called it the most important product launch in company history. Atera is meant to handle large-scale, whole-transcriptome spatial work, which means researchers can study where genes are active inside tissue at much greater scale.
This creates a near-term problem. Customers can delay buying older spatial instruments while they wait for Atera shipments in H2 2026. That helps explain why Q1 instrument revenue fell 24%.
The stock now turns on launch execution. If Atera ships on time and pulls in new labs, 10x can restart instrument growth and feed more future consumable demand. If it slips, demand is weak, or Xenium gets cannibalized without enough new demand, 2026 could stay soft.
Lab tools first, repeat kits later
10x sells instruments, then sells the proprietary chips, slides, reagents, and other consumables needed for each experiment. This is the razor and blade model: the machine gets placed in a lab, and each new experiment creates another sale.
The main customers are academic labs, government researchers, and biopharma companies. They use 10x tools to study cells, genes, and tissue structure. Software is bundled into the workflow, which helps keep customers inside the 10x system.
This model works best when instrument placements grow and each placed instrument gets used often. It breaks when labs delay big equipment orders, when grant budgets tighten, or when lower prices lift experiment volume but not enough revenue.
Q1 2026 shows both sides. Consumables revenue rose 13% to $129.8 million, but instruments fell to $11.3 million. Atera could fix the instrument side, but only if the launch creates enough new placements.
Single cell, spatial, and the Atera bet
Chromium
Chromium is the flagship single-cell platform. It helps researchers study many individual cells instead of averaging a whole tissue sample.
Visium
Visium maps gene expression while keeping the tissue layout in view. It is part of the spatial biology lineup, where location inside tissue matters.
Xenium
Xenium is a high-plex in situ platform, meaning it can image many RNA and protein targets inside tissue. It helped drive 31% spatial consumables growth in Q1 2026.
Atera
Atera is the new flagship spatial platform launched in Q1 2026. It is designed for high-throughput, whole-transcriptome spatial analysis at large scale.
Software tools
Cell Ranger, Xenium Explorer, and related software help customers process and view results. The software supports the hardware and consumables ecosystem.
Consumables carry the revenue mix
Segment mix uses Q1 2026 total revenue from the March 31, 2026 Form 10-Q. Consumables were the clear center of the business, while license and royalty revenue was small after a large 2025 settlement benefit faded.
What could break the thesis
Atera launch miss
High impact · Medium oddsAtera is now the main catalyst and the main execution risk. Customers are already delaying some instrument purchases while they wait for it. If shipments slip past H2 2026 or early uptake is weak, the company could miss its growth plan and lose time rebuilding instrument demand.
Longer instrument spending freeze
High impact · Medium oddsCapital equipment sales remain weak. Instrument revenue fell 39% in FY2025 and another 24% in Q1 2026. If labs keep delaying purchases, fewer new systems get placed, which can reduce future consumables pull-through.
NIH budget pressure
Medium impact · Medium oddsMany 10x customers depend on research grants. The 2025 Form 10-K called out uncertainty around a proposed 15% cap on NIH indirect cost reimbursement, even though courts had paused it. If funding pressure rises, labs may delay projects or buy fewer consumables.
China trade hit
Medium impact · Medium oddsChina was about 10% of 2025 revenue. The company warned that being added to China’s Unreliable Entity List could materially hurt or even eliminate that business. Tariffs can also pull orders forward in one quarter and leave a hole in the next.
AI hardware supply squeeze
Medium impact · Medium odds10x warned that the rapid buildout of AI infrastructure has stretched supply for GPUs and memory. Bigger tech buyers can get priority from suppliers. If 10x cannot get parts on time, instrument production could be delayed just as Atera needs a clean ramp.
Clinical market complexity
Medium impact · Low odds10x is looking beyond research-use-only tools and toward clinical or diagnostic use cases. That adds FDA, CLIA, reimbursement, and liability risk. A technical failure in a clinical setting could be more costly than a research tool issue.
In one breath
How does 10x Genomics make money?
It sells lab instruments and then sells the consumables needed to run experiments on those instruments. In Q1 2026, consumables were far larger than instruments, with $129.8 million of consumables revenue versus $11.3 million of instrument revenue.
Why did 10x Genomics instrument revenue fall?
Management said some spatial biology customers paused or delayed purchases before the Atera launch. Instrument revenue fell 24% in Q1 2026, so the next test is whether Atera shipments restart demand in late 2026.
What is Atera?
Atera is 10x Genomics’ new spatial biology platform launched in Q1 2026. It is designed for high-throughput, whole-transcriptome spatial analysis, which means studying where genes are active across tissue at large scale.
Is 10x Genomics profitable?
The company is still judged on growth and cash discipline more than steady profits. The 2025 update showed positive operating cash flow for the year, but the main debate is whether revenue growth can speed up again.